May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Efficacy of Transfer Factor in Treating Patients with Recurrent Herpes Keratitis
Author Affiliations & Notes
  • L. Meduri
    Pathophysiological Optics, University Bologna-Italy, Bologna, Italy
  • G. Pizza
    Immunotherapy Unit, 1st division of Urology, University Bologna-Italy, Bologna, Italy
  • C. De Vinci
    Immunotherapy Unit, 1st division of Urology, University Bologna-Italy, Bologna, Italy
  • M. Morara
    Immunotherapy Unit, 1st division of Urology, University Bologna-Italy, Bologna, Italy
  • D. Corazza
    Immunotherapy Unit, 1st division of Urology, University Bologna-Italy, Bologna, Italy
  • S. Vismara
    Immunotherapy Unit, 1st division of Urology, University Bologna-Italy, Bologna, Italy
  • R.A. Meduri
    Immunotherapy Unit, 1st division of Urology, University Bologna-Italy, Bologna, Italy
  • Footnotes
    Commercial Relationships  L. Meduri, None; G. Pizza, None; C. De Vinci, None; M. Morara, None; D. Corazza, None; S. Vismara, None; R.A. Meduri, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4743. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Meduri, G. Pizza, C. De Vinci, M. Morara, D. Corazza, S. Vismara, R.A. Meduri; Efficacy of Transfer Factor in Treating Patients with Recurrent Herpes Keratitis . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4743.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the efficacy of specific anti HSV Transfer Factor (TF) for recurrent Herpes keratitis treatment. Methods: 200 patients (112 women, 88 men, mean age 39±8.3 years, range from 22 to 66 years) affected by herpes keratitis were assessed for the presence of antibodies against HSV1 and were treated with orally administered TF . Follow up was 4±1 years before TF treatment and 2±1.5 years after TF treatment. Mean duration of treatment was 200±12 days. Clinical evaluation parameters were: number and duration of relapses calculated by a cumulative relapse index (R.I.) Immunological evaluation parameters were: the lymphocyte stimulation test (LST) and the leucocyte migration test (LMT). Results: Before treatment R.I. was 14.5±8.8, after treatment R.I. was 4.8±4.2, mean duration of relapses before treatment was 16.1±13.3, after treatment was 6.0±2.1. The LST and LMT showed statistical significant(p<0.01) differences before and after treatment. Conclusions: Specific anti HSV TF seems to be efficacious, associated with other usual antiviral drugs in preventing herpes keratitis relapses.

Keywords: keratitis • herpes simplex virus • immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×